Ling Ye

Dr. Ling Ye


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
LYLing Ye
Ling Ye
YHYuanlong Hou
Yuanlong Hou
WHWanyu Hu
Wanyu Hu
HWHongmei Wang
Hongmei Wang
RYRuopeng Yang
Ruopeng Yang
HHHao Haiping
Hao Haiping
Chronic stress is a known risk factor for breast cancer, yet the underlying mechanisms are unclear. This study explores the potential involvement of microbial and metabolic signals in chronic stress-promoted breast cancer progression, revealing that reduced abundances of Blautia and its metabolite acetate may contribute to this process. Treatment with Blautia and acetate increases antitumor responses of CD8+ T cells and reverses stress-promoted breast cancer progression in female mice. Patients with depression exhibit lower abundances of Blautia and acetate, and breast cancer female patients with depression display lower abundances of acetate, decreased numbers of tumor-infiltrating CD8+ T cells, and an increased risk of metastasis. These results suggest that Blautia-derived acetate plays a crucial role in modulating the immune response to breast cancer, and its reduction may contribute to chronic stress-promoted cancer progression. Our findings advance the understanding of microbial and metabolic signals implicated in cancer in patients with depression and may provide therapeutic options for female patients with breast cancer and depression.

5 June 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
LYLing Ye
Ling Ye
SFShicheng Fan
Shicheng Fan
PZPengfei Zhao
Pengfei Zhao
CWChenghua Wu
Chenghua Wu
MLMenghua Liu
Menghua Liu
HBHuichang Bi
Huichang Bi
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against COVID-19 remain urgently in need although vaccination significantly reduces the incidence, hospitalization, and mortality. At present, antiviral drugs including Nirmatrelvir/Ritonavir (PaxlovidTM), Remdesivir, and Molnupiravir have been authorized to treat COVID-19 and become more globally available. On the other hand, traditional Chinese medicine (TCM) has been used for the treatment of epidemic diseases for a long history. Currently, various TCM formulae against COVID-19 such as Qingfei Paidu decoction, Xuanfei Baidu granule, Huashi Baidu granule, Jinhua Qinggan granule, Lianhua Qingwen capsule, and Xuebijing injection have been widely used in clinical practice in China, which may cause potential herb-drug interactions (HDIs) in patients under treatment with antiviral drugs and affect the efficacy and safety of medicines. However, information on potential HDIs between the above anti-COVID-19 drugs and TCM formulae is lacking, and thus this work seeks to summarize and highlight potential HDIs between antiviral drugs and TCM formulae against COVID-19, and especially pharmacokinetic HDIs mediated by metabolizing enzymes and/or transporters. These well-characterized HDIs could provide useful information on clinical concomitant medicine use to maximize clinical outcomes and minimize adverse and toxic effects.

17 July 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ZWZhaoyu Wang
Zhaoyu Wang
YLYao Lan
Yao Lan
MCMingHao Chen
MingHao Chen
CWCailing Wen
Cailing Wen
YHYanxian Hu
Yanxian Hu
LYLing Ye
Ling Ye

22 May 2019 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
RSRongjin Sun
Rongjin Sun
MCMinghao Chen
Minghao Chen
YHYanxian Hu
Yanxian Hu
YLYao Lan
Yao Lan
LGLili Gan
Lili Gan
LYLing Ye
Ling Ye

7 March 2020 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
LGLili Gan
Lili Gan
JMJiating Ma
Jiating Ma
GYGuoquan You
Guoquan You
JMJinxia Mai
Jinxia Mai
ZWZhaoyu Wang
Zhaoyu Wang
LYLing Ye
Ling Ye

12 September 2024 in Gut Microbes
Verified
Journal Article
Open access
DTDafu Tang
Dafu Tang
WHWanyu Hu
Wanyu Hu
BFBingxuan Fu
Bingxuan Fu
XZXiaojie Zhao
Xiaojie Zhao
GYGuoquan You
Guoquan You
LYLing Ye
Ling Ye
Cholestatic liver injury results from the accumulation of toxic bile acids in the liver, presenting a therapeutic challenge with no effective treatment available to date. Andrographolide (AP) has exhibited potential as a treatment for cholestatic liver disease. However, its limited oral bioavailability poses a significant obstacle to harnessing its potent therapeutic properties and restricts its clinical utility. This limitation is potentially attributed to the involvement of gut microbiota in AP metabolism. In our study, employing pseudo-germ-free, germ-free and strain colonization animal models, along with 16S rRNA and shotgun metagenomic sequencing analysis, we elucidate the pivotal role played by gut microbiota in the C-sulfonate metabolism of AP, a process profoundly affecting its bioavailability and anti-cholestatic efficacy. Subsequent investigations pinpoint a specific enzyme, adenosine-5'-phosphosulfate (APS) reductase, predominantly produced by Desulfovibrio piger, which catalyzes the reduction of SO42- to HSO3-. HSO3- subsequently interacts with AP, targeting its C=C unsaturated double bond, resulting in the formation of the C-sulfonate metabolite, 14-deoxy-12(R)-sulfo andrographolide (APM). Inhibition of APS reductase leads to a notable enhancement in AP bioavailability and anti-cholestatic efficacy. Furthermore, employing RNA sequencing analysis and farnesoid X receptor (FXR) knockout mice, our findings suggest that AP may exert its anti-cholestatic effects by activating the FXR pathway to promote bile acid efflux. In summary, our study unveils the significant involvement of gut microbiota in the C-sulfonate metabolism of AP and highlights the potential benefits of inhibiting APS reductase to enhance its therapeutic effects. These discoveries provide valuable insights into enhancing the clinical applicability of AP as a promising treatment for cholestatic liver injury.